2 August 2021
Latham & Watkins Advises Abcam on US$340 Million Acquisition of BioVision
Advising firms
Deal team
7 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Kate Withers Lead | Latham & Watkins LLP | Partner | Not stated | New York |
| David Blumental Lead | Latham & Watkins LLP | Partner | Not stated | Hong Kong |
| Robbie McLaren Lead | Latham & Watkins LLP | Partner | Not stated | London |
| Wayne Yu | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Andrew Rondeau | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Yujie Zhang | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Yi Peng | Latham & Watkins LLP | Associate | Not stated | Not stated |
4 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 340m (US$340 million)
- What the figure measures
- Total transaction value
- Client
- Abcam plcBuy-side
- Counterparties
- BioVision, Inc. (Target)
Boai NKY Medical Holdings Ltd. (Sell-side)